Format

Send to

Choose Destination
Clin Pharmacol Ther. 2012 Sep;92(3):332-9. doi: 10.1038/clpt.2012.108. Epub 2012 Aug 8.

Alanine aminotransferase: a clinical and regulatory tool for detecting liver injury-past, present, and future.

Author information

1
Office of Pharmacovigilance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Federal Research Center at White Oak, Silver Spring, Maryland, USA. john.senior@fda.hhs.gov

Abstract

Assay of the serum activity of the enzyme alanine aminotransferase (ALT) has become the primary screening tool for detecting acute liver injury. But what does an elevated value mean? Not what it is too often mistakenly believed to indicate. It is not a test of liver function. It does not necessarily predict worse effects to come (in a given person). It is not a valid measure of severity of liver injury or dysfunction. It is too unspecific to be reliable in screening for relatively rare effects on the liver. Although these are substantial limitations, ALT is a very useful biomarker if understood and used properly. It is important to consider how and why these erroneous concepts came to have such wide acceptance, and how elevations of ALT activity for evaluating patients and subjects under study might be interpreted better.

PMID:
22871997
DOI:
10.1038/clpt.2012.108
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center